Search

Displaying results 4111 - 4120 of 7063 in total
  1. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    Remibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. … [L54101] Bruton's tyrosine kinase plays a role in B cell receptor and Fc receptor signalling, releasing histamine and pro-inflammatory mediators.

  2. Drug

    Lotiglipron

    go.drugbank.com/drugs/DB21631
    Investigational

    Lotiglipron has a monoisotopic molecular weight of 574.2 Da. … Lotiglipron is a small molecule drug. The usage of the INN stem '-glipron' in the name indicates that Lotiglipron is a glucagon-like peptide 1 receptor (GLPIR) agonist.

  3. Drug

    Tocotrienol

    go.drugbank.com/drugs/DB12647
    Investigational

    Tocotrienol has been investigated for the treatment of Cholesterol Lowering.

    Mixtures: NHF Tocotrienol E Plus Vitamin D3 SoftgelCategories: Compounds used in a research, industrial, or household setting
  4. Drug

    Montmorillonite

    go.drugbank.com/drugs/DB13654
    Investigational

    Mixtures: Dr. SEED Teatree and Lime Vegan No-sebum Cool Anti HairlossShampooCategories: Compounds used in a research, industrial, or household setting
  5. Drug

    Rusfertide

    go.drugbank.com/drugs/DB17724
    ApprovedInvestigational

    [L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer. … Rusfertide is a hepcidin mimetic used to treat erythrocytosis in adults with polycythemia vera.

  6. Drug

    TGAAC94

    go.drugbank.com/drugs/DB06175
    Investigational

    The Health Recombinant DNA Advisory Committee (RAC) concluded that a possible role of the gene transfer in this clinical course could not definitively be excluded due to the lack of data. [A264038] … tgAAC94 is a recombinant adeno-associated virus serotype 2 (AAV2) vector containing the cDNA for a human tumor necrosis factor receptor (TNFR)-immunoglobulin (IgG1) Fc fusion (TNFR:Fc) gene.

  7. Drug

    Strontium chloride Sr-89

    go.drugbank.com/drugs/DB09498
    Approved

    Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. … [A31264] Bone metastases is a common and severe complication presented in advanced stages of the disease.

  8. Drug

    Deoxycholic acid

    go.drugbank.com/drugs/DB03619
    ApprovedInvestigational

    Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that … In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity.

  9. Drug

    Alosetron

    go.drugbank.com/drugs/DB00969
    ApprovedWithdrawn

    In June 2002, the FDA approved a supplemental new drug application allowing the remarketing of the drug under restricted conditions of use. … Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women.

  10. Drug

    Buclizine

    go.drugbank.com/drugs/DB00354
    Approved

    It was manufactured by Stuart Pharms and initially approved by the FDA in 1957.